

Industry Sponsored Session • Sunday, 17 January 2021

“Exciting news around treatment with incobotulinumtoxinA”

Sunday, January 17th, 2021, 12:50 PM to 2:00 PM EST / 18:50-20:00 CET

Moderator: **Keith W. Burke**

Vice President of Marketing, Merz Pharmaceuticals, LLC., Raleigh, NC, USA

Now Approved in USA, First and Only BotulinumtoxinA with FDA approval to help children with chronic drooling

Elizabeth Moberg-Wolff, M.D.

*Pediatric Rehabilitation Medicine Associates,
Milwaukee, WI, USA*

Prof. Steffen Berweck

Schön Clinic, Vogtareuth, Germany

Why immunogenicity matters with Botulinum toxin treatment

Warner W. Carr, M.D.

*Food Allergy Center of Southern California
Mission Viejo, CA, USA*

Prof. Harald Hefter

Heinrich Heine University Düsseldorf, Germany

Free registration at <https://www.neurotoxins.org/toxins-2021-virtual/>

Supported by



THERAPEUTICS

Better outcomes for more patients.